Instrument: RSLCnano HPLC system  
Instrument: LTQ-Orbitrap-Velos mass spectrometer  
FragmentationMethod: higher-energy collision dissociation  
CollisionEnergy: normalized collision energy of 42.5  
IonizationType: positive ion mode  
Separation: reverse-phase trap column  
Separation: reverse-phase PicoFrit capillary column  
FlowRateChromatogram: 0.3 μl min−1  
GradientTime: 4 h  
CleavageAgent: trypsin  
PrecursorMassTolerance: 10 p.p.m.  
FragmentMassTolerance: 0.02 Da  
EnrichmentMethod: IMAC  
EnrichmentMethod: titanium dioxide  
FractionationMethod: anion exchange  
ReductionReagent: DTT  
AlkylationReagent: iodoacetamide  
Organism: Plasmodium falciparum  
SourceName: O+ human RBC  
CellLine: P. falciparum blood stage 3D7  
CellLine: PKGT618Q  
CellLine: CDPK1-HA parasites  
GeneticModification: PfPKGT618Q mutant  
GeneticModification: CDPK1-KD  
Compound: Compound 2  
ConcentrationOfCompound: 2 μM Compound 2  
Compound: E-64  
ConcentrationOfCompound: 10 μM E-64  
Compound: WR99210  
ConcentrationOfCompound: 10 nM WR99210  
Time: 60 min  
Temperature: 37 °C  
NumberOfBiologicalReplicates: three independent experiments  
AssayName: tandem mass tag labelling  
AssayName: LC-MS/MS  
AssayName: quantitative global phosphoproteomics  
PooledSample: TMT-labelled samples were pooled  
MaterialType: parasite lysates  
SampleTreatment: saponin treatment  
DevelopmentalStage: late schizont stage  
Experiment: in vitro kinase assay